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vival (PFS) and progressive disease, using a parametric extra-
polation of the NO16966 phase III trial survival data. The
predicted time spent in each health state was weighted using
published CRC utility scores to account for patient quality of life
and to estimate the Quality Adjusted Life Years (QALYs) for
both bevacizumab + XELOX and FOLFOX. One-way sensitivity
analysis was performed in order to evaluate the uncertainty
around the base case estimate of the incremental cost effective-
ness ratio (ICER) for bevacizumab + XELOX compared with
FOLFOX. Uncertainty surrounding the parameters of the model
was evaluated by modifying the costs and parametric survival
assumptions. RESULTS: The base case cost per QALY was esti-
mated to be £25,806. The highest ICER was observed when only
a 2-year time horizon was taken (£35,241); this, however, does
not capture all the costs and beneﬁts of the interventions. The
ICER for the scenario in which 100% of FOLFOX patients did
not require an inpatient stay was £31,669 and decreased to
£14,431 when full sensitivity analysis of the administration costs
was performed. CONCLUSIONS: This sensitivity analysis illus-
trated that the combination of bevacizumab and XELOX dem-
onstrated a stable ICER. Substantial cost savings and health
beneﬁts gain through the use of capecitabine and oxaliplatin in
combination with bevacizumab showed to be a cost-effective
treatment strategy.
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OBJECTIVES: Radiotherapy (RT) with charged particles,
protons and carbon ions (c-ions) offers clinical advantages in
cancer treatment compared to conventional RT with photons,
including better tumor control and/or less side-effects. The costs
of particle therapy (PT) are however, much higher then of the
photon therapy. Therefore, the cost-effectiveness of PT as
opposed to the best current photon therapy was examined.
METHODS: In a cost-effectiveness Markov model the prostate
cancer treatments with (A) c-ions and (B) photons were evalu-
ated. The outcomes were survival, quality adjusted survival and
costs. The therapy effects and quality of life estimates were
derived from the literature. Toxicity of treatment was taken into
account. Direct medical costs were assigned. The RT costs were
based on an extensive cost analysis. The time horizon of the
model was 10 years. The analyses were run for a cohort of 70
year old. The study was performed from the health care per-
spective. RESULTS: The expected total health care costs per
patient over 10 years were: A) €22,880, and B) €13,550. The
expected life years were 8.78 and 8.68, respectively. The differ-
ence in the clinical effects became larger, when quality of life
was accounted for. The quality of life adjusted life years
(QALY’s) were A) 7.82 and B) 7.59. Extra costs per QALY
gained were €40,170 (up to €65,000 in a sensitivity analysis).
CONCLUSIONS: The preliminary results indicate that with a
threshold of €80,000 per QALY, treatment with c-ions is cost-
effective (for age 70). The model will be further adapted. Firstly,
treatment with protons will be included. Secondly, analyses will
be performed for different age and risk categories. Thirdly, the
probability that the different treatment modalities are cost-
effective, given the existing uncertainty, will be assessed. Finally,
an expected value of perfect information (EVPI) analysis will be
conducted.
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OBJECTIVES: Evaluation of costs of oral capecitabine and cis-
platin (XP) treatment vs. intravenous 5FU and cisplatin (FP)
infusion from public payer’s perspective in Poland. METHODS:
Based on systematic review of medical databases similar clinical
efﬁcacy for compared treatment options was proved. Therefore a
cost minimization analysis was performed to identify costs and
estimate potential beneﬁts of 5FU/cisplatin replacement with
capecitabine/cisplatin scheme, from public payer perspective.
Efﬁcacy and safety data were derived from clinical trial published
by Y.Kang et al. (JCO, 2006 ASCO Annual Proceedings). A
pharmacoeconomic model was used to compare costs of these
two therapies. Costs of alternative therapies were estimated
based on clinical results on actual dose and number of adminis-
trations. Clinical experts panel estimated typical treatment pat-
terns and costs of treating major AEs in Poland. RESULTS: Mean
duration of hospitalization in XP arm was 5.11 days and in FP
arm was 22.15 days. The substitution of 5-FU infusion by oral
capecitabine reduced the number of hospitalization days per
cycle. Drug administration costs were signiﬁcantly higher on FP
scheme (8800PLN) in comparison to XP (1515PLN). Total drug
cost per patient on XP scheme was 6384. 41PLN (1 PLN = 3.4
EUR) and 708.20PLN on FP scheme. AE proﬁles were similar.
Total costs (drug, administration and AE) was lower for XP
scheme, generating 1614.12PLN savings per patient/year. Sensi-
tivity analysis was conducted for number of patients treated with
5FU/cisplatin requiring intravenous access and for the drug reim-
bursement level. Reimbursement level doesn’t inﬂuence conclu-
sions drawn from the basic analysis. Change in percentage of
patients requiring intravenous access inﬂuence the conclusions
(breaking point 43%). CONCLUSIONS: Replacing 5FU/
cisplatin scheme with capecitabine/cisplatin in treatment of
advanced gastric cancer patients from public payer in Poland is
cost saving.
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OBJECTIVES: The randomized COST trial revealed no signiﬁ-
cant differences in clinical or quality-of-life endpoints between
LAC and OC for stage I-III colon cancer. We conducted a cost-
minimization analysis from a third-party payer perspective to test
for differences in costs between procedures from surgery through
2 months of follow-up. METHODS: Resource use was collected
on all patients, including: inpatient and ICU days, reoperations,
surgery and anaesthesia times, use of laparotomy and laparo-
scopic instruments, cartridges, reusable and disposable trocars,
and outpatient visits for surgery-related complications. Profes-
sional services were valued based on Medicare reimbursement
rates; all other unit costs were derived from charges adjusted by
ratios-of-costs-to-charges for patients treated at two centers, one
academic (A) and one community (C). 21% of patients assigned
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to the LAC arm who were converted to open colectomy were
included in the LAC group in the analysis. RESULTS: Among
855 patients, length of stay (mean: 5.5 vs. 6.7 days) was signiﬁ-
cantly shorter, while operating time was signiﬁcantly longer
(mean: 166 vs. 109 minutes) in the LAC arm. More costly OR
supplies were used in the LAC arm. Resource use was otherwise
similar between arms. The incremental costs were either mod-
estly higher in the LAC arm, $2,454 (95% CI $1,421–$3,485,
2007 US $) (C), or not statistically different, -$62 (95% CI
-$1,759–$1,608) (A) depending on the source of unit costs.
CONCLUSIONS: Economically, the choice between LAC and
OC consists of a tradeoff between higher operative costs and
shorter length of stay. The direction and magnitude of the net
effect depends on the cost inputs from a given institution, with
LAC relatively less expensive in institutions with higher ″hotel″
costs and less costly operative supplies. Future research should
focus on structured peri- and post-operative care to further opti-
mize the care and costs associated with LAC.
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OBJECTIVES:Capecitabine (Xeloda) is an effective alternative to
treat metastatic colorectal cancer (mCRC) patients. This study
compares the costs of capacetabine and UFT/Leucovorin (UFT/
LV) in ﬁrst line therapy for patients with mCRC in Brazil.
METHODS: An analytic-decision model for projecting costs of
treating mCRC in Brazil was developed considering local guide-
lines, to compare costs of capecitabine (2500 mg/m2/day, d1-d14;
21 days-cycle) and UFT/LV (300 mg/m2/day of UFT, d1-d28; 35
days-cycle; 70mg of LV per day), under the payer perspective. The
time horizon of this analysis was 3.5-months, based on the
progression free survival (PFS) of UFT/LV showed in Douillard,
et al 2002 trial. In the absence of head-to-head trials, the same
efﬁcacy, in terms of PFS, was assumed for capecitabine and
UFT/LV. The safety proﬁles were obtained from Twelves, et al
2001 and Douillard, et al 2002. A panel of Brazilian specialists
was conducted to identify the local practices for treating adverse
events (AE). Costing was conducted based on public lists. For the
base case scenario a 1,7 m2 body surface patient was considered.
One-way sensitivity analysis was conducted to check the robust-
ness of the results. RESULTS: The total treatment cost of capecit-
abine is lower than UFT/LV: R$11,908 for capecitabine vs
R$19,417 for UFT/LV. Capecitabine has a lower acquisition cost
(R$3,205/month) than the UFT/LV scheme (R$4,457/month).
Capecitabine shows a better safety proﬁle thus costs for AE
management are lower thanUFT/LV (R$196 for CAP vs. R$1,089
forUFT/LV).CONCLUSIONS: Findings suggest capecitabine as a
cost-saving therapy under the payers’ perspective in Brazil. Total
savings could reach R$7,509 for a 3.5 month-period treatment.
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OBJECTIVES: An economic analysis was undertaken alongside
a trial evaluating chemotherapy with FOLFOX6: (5Fluouracil/
Leucovorin/Oxaliplatin) versus XELOX: (Capecitabine/
Oxaliplatin) as an adjuvant postoperative therapy for high risk
colorectal cancer patients. METHODS: In the absence of sur-
vival difference, a cost-minimisation analysis was undertaken.
Individual patient data (n = 169) were combined with 2008 unit
prices to estimate the cost of chemotherapy, administration,
medical consumables, drugs and laboratory testing. Patient
addresses were used to estimate travelling expenditure and
income data to evaluate productivity losses for those at produc-
tive ages. Raw data were bootstrapped 5000 times to correct for
distortions and to undertake statistical testing. RESULTS: From
a hospital perspective, the mean patient chemotherapy cost was
€8,866 with FOLFOX6 and €9723 with XELOX. Administra-
tion cost was €5,212 and €1,051, erythropoietin €2,787 and
€1,744 and total treatment cost €17,485 and €12,524 respec-
tively. Thus, XELOX reduced overall treatment cost by €4,961
(p  0.01). From a social insurance perspective, the mean che-
motherapy cost was €9,265 with FOLFOX6 and €10,160 with
XELOX. Administration cost was €3,113 and €185, erythropoi-
etin €2,789 and €1,713 and total treatment cost €15,797 and
€12,116 respectively. Thus, XELOX reduced total treatment cost
by €3680 (p  0.01). Mean patient travelling cost was €184 with
FOLFOX6 and 80€ with XELOX, a difference of €104 (p 
0.01). Mean productivity loss was €100 with FOLFOX6 and €31
with XELOX, a difference of €69 (p  0.01). CONCLUSIONS:
Apart from being more convenient for patients, oral chemo-
therapy with Capecitabine(Xeloda) reduces total treatment cost
for the NHS and Insurance Funds, as it reduces drastically the
cost of administration. It also reduces patient travelling time and
cost and productivity loss. Hence, it represents a cost saving and
advantageous approach to the management of operated colorec-
tal cancer patients.
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OBJECTIVES: A cost-minization analysis compared total costs
of XELOX (capecitabine + oxaliplatin) versus FOLFOX-6
(5-FU + folinic acid + oxaliplatin) in the ﬁrst line treatment for
patients with metastatic colorectal cancer (mCRC) in Brazil.
METHODS: An analytic-decision model for projecting costs of
treating mCRC in Brazil was developed considering local guide-
lines and the Brazilian payers’ perspective. According to the
phase III trial of Ducreux et al 2007, we assumed the same
efﬁcacy for XELOX and FOLFOX-6 in terms of progression
free-survival and overall survival. Only direct costs (drugs, IV
administration, physician fees, materials, etc.) were considered
for the chemotherapy and for treating adverse events. The time-
horizon of this analysis was 126 days according to the mean
number of Progression Free Survival found in the Ducreux clini-
cal trial (6 cycles of XELOX and 9 cycles of FOLFOX-6). For the
base case a patient with 1.7 m2 was considered. A Delphi panel
was conducted to identify local practices to manage the adverse
events of each scheme. Discount rate was not necessary because
of the short length of the analysis. RESULTS: Drug acquisition
costs for FOLFOX-6 were higher than XELOX (R$66,433 vs.
R$59,657). XELOX treatment generated a R$15,465 saving per
patient due to a 92% reduction in the number of IV administra-
tions. XELOX also presented a reduction of R$2,121.65 in costs
related to the management of adverse events. A one-way sensi-
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